Hepatitis C treatment in China is facing severe challenges. New drugs may change the status quo

  Recently, Roche and Geli Biotechnology (Hangzhou) Co., Ltd (hereinafter referred to as "Geli") jointly announced that they would cooperate in the R & D and production of new Roche hepatitis C drug danoprevir in China According to the 2012 online survey on public cognition of hepatitis, 97% of the respondents think they know something about hepatitis C, which is a significant increase compared with 2007 However, only 14% of the respondents have a correct understanding of hepatitis C according to their responses to the transmission and prevention methods of hepatitis C At present, there are about 10 million patients with chronic hepatitis C in China, most of them are 1b type Patients with this genotype have been shown to have a high response rate to danoprevier Therefore, Roche and Geli decided to jointly develop the new drug, which will help alleviate the serious public health problem of hepatitis C and provide a new and effective treatment scheme for the vast number of hepatitis C patients in China Speaking of the cooperation, Mr Lu Ke, President of Roche pharmaceutical Asia Pacific region, said: "the starting point of Roche's strategy is to bring innovative and differentiated drugs to patients The decision to develop danoprevir is due to its bright future in the treatment of hepatitis C 1B gene patients " Dr Wu JINZI, President and CEO of Geli Biotechnology (Hangzhou) Co., Ltd., said: "currently, there is no hepatitis C treatment drug (DAAS) that directly affects the virus in the Chinese market." This cooperation will customize this innovative hepatitis C drug for Chinese patients and eventually bring it to the market Up to now, danoprevir's clinical trial data are very encouraging, and we look forward to this innovative drug benefiting more hepatitis C patients as soon as possible "